ArticleInternational journal of molecular sciences2018
A Novel Marker of Inflammation: Azurocidin in Patients with ST Segment Elevation Myocardial Infarction.
Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Kinetics and prognostic value of heparin binding protein at the ST-segment-elevation myocardial infarction.Annals of medicine · 2026Article
- Evaluation of Heparin-Binding Protein as a novel biomarker for the detection of periprosthetic joint infection.Frontiers in cellular and infection microbiology · 2025Article
- Association of heparin-binding protein with risk of in-hospital heart failure in patients with acute coronary syndrome.American journal of translational research · 2025Article
- Heparin-binding Protein as a Diagnostic and Prognostic Marker of Infections: A Systematic Review and Meta-analysis.Mediterranean journal of hematology and infectious diseases · 2025Review
- Uric Acid to Albumin Ratio as a Predictive Marker for Intracoronary Thrombus Severity in ST-Segment Elevation Myocardial Infarction (STEMI) Patients Undergoing Primary Percutaneous Coronary Intervention (PCI).Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Cluster analysis of clinical, angiographic, and laboratory parameters in patients with ST-segment elevation myocardial infarction.Lipids in health and disease · 2024Article
- Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris.Experimental dermatology · 2022Article
- Neutrophil degranulation and myocardial infarction.Cell communication and signaling : CCS · 2022Review
- Bioinformatic Analysis for Potential Biomarkers and Therapeutic Targets of T2DM-related MI.International journal of general medicine · 2021Article
- Proteomic Biomarkers of Retinal Inflammation in Diabetic Retinopathy.International journal of molecular sciences · 2019Review
- A Promising Candidate: Heparin-Binding Protein Steps onto the Stage of Sepsis Prediction.Journal of immunology research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) To investigate the role of azurocidin, an antimicrobial protein, in patients with ST segment elevation myocardial infarction (STEMI). (2) This single-center prospective observational study included patients with STEMI and healthy age- and sex-matched control subjects. Baseline demographic, clinical and biochemical data were compared between the two groups. Azurocidin levels at baseline were determined using an enzyme-linked immunosorbent assay. Multivariate linear regression analysis with enter method was used to test the association between azurocidin and independent variables, such as the thrombolysis in myocardial infarction (TIMI) score, synergy between percutaneous coronary intervention with TAXUS and cardiac surgery score, global registry of acute coronary events score, Killip class, C-reactive protein (CRP), and creatinine kinase-myocardial band (CK-MB). (3) A total of 76 patients with STEMI and 30 healthy control subjects were enrolled in the study. Mean ± SD azurocidin levels were significantly higher in patients compared with healthy controls (18.07 ± 13.99 versus 10.09 ± 5.29 ng/mL, respectively). In a receiver-operating characteristic curve analysis, an azurocidin cut-off level of >11.46 ng/mL had 74% sensitivity and 58% specificity in predicting myocardial infarction. Azurocidin levels had a positive correlation with TIMI score (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.